December 13, 2024 8:01am

An econ light session; time to “go fish”? Selectively!

Pre-open Indications: 3 Negative and 2 Positive Indications

Prices for U.S. imports increased 0.1% in November, after rising 0.1% in October. U.S. export prices were unchanged in November following a 1.0% advance the previous month. Over the past year, import prices increased 1.3% and export prices rose 0.8%.

As I have written, “uncle algo and his trading dwarfs” determine the heights or lows of share pricing”

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

Thursday’s night’s … RegMed Investors (RMi) Closing Bell: the haunting of share pricing continues … https://www.regmedinvestors.com/articles/13733

 

Friday: The pre-open Dow futures are UP +0.15% or (+65 points), the S&P futures are UP +0.36% or (+21 points) and the Nasdaq futures are UP +0.81% or (+174 points)

  • Stock futures were “streaming” higher Friday, 
  • European markets were trading lower,
  • Asia-Pacific markets fell.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Indexes fell Thursday, weighed down by a hotter-than-expected U.S. inflation report, as the cell and gene therapy sector bottomed even more so far this week.

The Nasdaq slid 0.66%, dipping back below the 20,000, the S&P 500 shed 0.54% while the Dow lost 0.53%.

Economic Data Docket: Import prices, month-over-month, November (-0.3% expected, +0.3% prior); Export prices, month-over-month, November (-0.3% expected, +0.8% prior)

 

Q4/24: December = 7 negative and 2 positive closes

  • November 10 negative and 9 positive closes
  • October: 8 positive and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context 

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Negative Indications:

Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Beam Therapeutics (BEAM) closed down -$0.84 after Wednesday’s -$1.30, Tuesday’s +$2.69, Monday’s +$0.81 and last Friday’s +$1.39 following the previous Thursday’s -$0.70 with a negative -$0.40 or -1.43% pre-open.

Lenz Therapeutics (LENZ) closed down -$2.24 after Wednesday’s -$0.94 after Tuesday’s +$0.86 after Monday’s -$3.85 with a negative -$0.78 or -2q.53% pre-open

uniQure NV (QURE) closed down -$#0.59 after Wednesday’s +$0.35, Tuesday’s +$8.01 and Monday’s -$0.15 with a negative -$0.26 or -1.73% aftermarket

Positive indications:

Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Blueprint Medicine (BPMC) closed down -$1.89 after Wednesday’s -$0.92, Tuesday’s +$0.82 and Monday’s -$1.40 with a positive +$0.72 or +0.78% pre-open

CRISPR Therapeutics (CRSP) closed down -$2.38 after Wednesday’s -$0.90, Tuesday’s -$1.16 after Monday’s -$2.49 with a positive +$0.11 or +0.24% aftermarket

 

The BOTTOM LINE: We have been subject to momentum reversals …

As I am STILL suspicious of the sector’s “froth” heading into this week ends as it runs.

There are clear winners with mostly losers in December …

  • Think about it; the biggest problem the cell and gene therapy sector has …  99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject to debt servicing firms!

 

I seem to be asking a question followed by a question …

  • Do we need to brace ourself for more economics and their down trending affect?
  • Is this market STILL “bubblicious” my concerns are macroeconomic and valuation

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.